1. Median overall survival increased by 3.2 months in the sacituzumab govitecan group compared to chemotherapy. 2. One fatal treatment-related ...
1. Progression-free survival was greater in the trastuzumab group compared to standard care (17.8 months vs. 6.9 months). 2. Drug-related ...
1. Median progression-free survival was longer in the SG group than in the chemotherapy group. 2. Median overall survival was ...
Click to read this study in The Lancet Oncology.
Click to read this study in The Lancet Oncology.
1. Median overall survival is longer for HER2-low breast cancer patients receiving trastuzumab deruxtecan compared with other chemotherapy treatment options. ...
1. Compared to trastuzumab emtansine, trastuzumab deruxtecan is associated with a lower risk of disease progression or death in patients ...
Click to read this study in JAMA Network Open.
1. Ribociclib plus letrozole provides significant overall survival benefit as compared to letrozole alone in patients with advanced breast cancer. ...
1. The incremental cost-effectiveness ratio of the pertuzumab group was $436,679 per QALY gained. 2. Even if pertuzumab were free, ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
